IRIDEX (NASDAQ:IRIX) Announces Quarterly Earnings Results, Misses Estimates By $0.06 EPS

by · The Cerbat Gem

IRIDEX (NASDAQ:IRIX – Get Free Report) issued its earnings results on Tuesday. The medical equipment provider reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.06), Zacks reports. The company had revenue of $12.57 million for the quarter, compared to the consensus estimate of $13.59 million.

Here are the key takeaways from IRIDEX’s conference call:

  • Glaucoma remained a growth engine, with Cyclo G6 probe volume up 35% year over year to 17,700 units and G6 product-family revenue up 19% to $3.9 million, supported by higher utilization, reimbursement tailwinds, targeted physician outreach, and higher U.S. pricing.
  • IRIDEX generated positive cash flow in the quarter while reducing operating expenses 5% year over year to $5.3 million. Management expects the headquarters relocation and shift to lower-cost contract manufacturing to improve margins and cash generation, particularly in 2027.
  • Second-quarter revenue fell 7% to $12.6 million, primarily because retina revenue declined to $6.5 million from $8.0 million. Retina performance was affected by international commercial transitions, regulatory constraints, distributor inventory issues, and operational execution challenges.
  • Management reaffirmed 2026 revenue guidance of $51 million to $53 million, excluding the Middle East, implying 1% to 5% pro forma growth. The company expects low-single-digit retina growth and low-double-digit glaucoma probe growth in the second half, but warned that international ordering may remain uneven and that safety-stock investments will reduce cash on hand through 2026.

IRIDEX Stock Performance

NASDAQ IRIX opened at $0.78 on Thursday. The business’s 50 day moving average price is $1.00 and its 200-day moving average price is $1.13. IRIDEX has a fifty-two week low of $0.70 and a fifty-two week high of $1.65. The company has a market cap of $13.63 million, a P/E ratio of -3.91 and a beta of 0.66.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 6th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, IRIDEX currently has an average rating of “Hold” and a consensus price target of $3.00.

Check Out Our Latest Report on IRIX

Institutional Investors Weigh In On IRIDEX

Hedge funds and other institutional investors have recently made changes to their positions in the company. Jane Street Group LLC lifted its holdings in shares of IRIDEX by 93.9% in the 4th quarter. Jane Street Group LLC now owns 31,758 shares of the medical equipment provider’s stock worth $36,000 after acquiring an additional 15,377 shares during the last quarter. Susquehanna International Group LLP raised its position in IRIDEX by 46.2% in the 3rd quarter. Susquehanna International Group LLP now owns 56,470 shares of the medical equipment provider’s stock worth $65,000 after purchasing an additional 17,834 shares during the period. Apexium Financial LP raised its position in IRIDEX by 53.0% in the 3rd quarter. Apexium Financial LP now owns 100,529 shares of the medical equipment provider’s stock worth $116,000 after purchasing an additional 34,834 shares during the period. Finally, Citadel Advisors LLC lifted its stake in IRIDEX by 62.7% in the third quarter. Citadel Advisors LLC now owns 109,473 shares of the medical equipment provider’s stock worth $126,000 after purchasing an additional 42,202 shares during the last quarter. Hedge funds and other institutional investors own 20.10% of the company’s stock.

About IRIDEX

(Get Free Report)

IRIDEX Corporation (NASDAQ: IRIX) is a medical technology company specializing in the development, manufacturing and commercialization of innovative ophthalmic laser and imaging systems. The company’s offerings focus on energy-based therapies designed to treat retinal vascular disorders, glaucoma and other ocular conditions. IRIDEX’s portfolio includes laser photocoagulation platforms, micro-pulse laser technology, and related consumable devices for use by ophthalmologists and retina specialists.

The company’s flagship products include the Cyclo G6 Glaucoma Laser System, which delivers precise, controlled micro-pulse laser therapy for patients with refractory glaucoma, and the IQ 532 Retina Laser System, designed to support minimally invasive laser treatments for diabetic retinopathy and age-related macular degeneration.

Read More